Eslicarbazepine

Introduction Overview

Generic Name

Eslicarbazepine

Brand Name

Aptiom

Dosage Form

Oral tablet

Drug Class

Dibenzazepine anticonvulsants

Pharmacokinetics

Absorption

Eslicarbazepine acetate, the prodrug form administered orally, is rapidly and extensively absorbed from the gastrointestinal tract. Following ingestion, it undergoes near-complete hydrolysis to its active metabolite, eslicarbazepine, resulting in high bioavailability of the active compound. Food intake does not significantly affect the rate or extent of absorption, allowing dosing without regard to meals. Peak plasma concentrations of eslicarbazepine are typically achieved within 2 to 3 hours post-dose. The absolute bioavailability of eslicarbazepine following oral administration is approximately 90%. Absorption may be influenced by gastrointestinal motility and pH but remains consistent across patient populations.

Distribution

Eslicarbazepine distributes moderately into body tissues with a volume of distribution ranging from 12 to 20 liters. The drug exhibits relatively low plasma protein binding, approximately 30%, primarily to albumin, which limits the risk of displacement interactions. Its distribution into the central nervous system is adequate to exert anticonvulsant effects, crossing the blood-brain barrier effectively. Distribution kinetics are largely unaffected by age, gender, or renal function, though caution is advised in special populations. The moderate volume of distribution suggests eslicarbazepine is largely confined to extracellular fluids.

Metabolism

Eslicarbazepine acetate is rapidly converted by first-pass hydrolysis primarily by esterases in the intestinal wall and liver to eslicarbazepine, which is pharmacologically active. Eslicarbazepine undergoes minimal further metabolism, with a small proportion converted to an inactive (R)-licarbazepine and glucuronide conjugates. Cytochrome P450 enzymes are minimally involved, reducing the potential for drug-drug interactions mediated by hepatic metabolism. The metabolic pathway results in stable plasma concentrations and predictable pharmacokinetics. Genetic polymorphisms in metabolic enzymes minimally impact its metabolism.

Elimination

Eslicarbazepine is eliminated predominantly via renal excretion, with approximately 90% of the administered dose excreted in urine within 72 hours, mainly as unchanged active metabolite and glucuronide conjugates. The elimination half-life ranges between 13 to 20 hours, allowing once-daily dosing. Renal clearance correlates with creatinine clearance, necessitating dose adjustments in patients with renal impairment. Hepatic impairment has limited effect on elimination due to the minor role of liver metabolism. Eslicarbazepine does not undergo significant biliary excretion or enterohepatic recirculation.

Dosage Forms

Adults

Aptiom is administered orally once daily. Initial dosing typically begins at 400 mg once daily; however, some patients may be initiated at 800 mg daily if the clinical situation warrants more rapid seizure control and benefits outweigh risks. Dosage titration can be performed by increasing 400 to 600 mg weekly based on therapeutic response and tolerability. Maintenance doses range between 800 mg to 1600 mg once daily. For monotherapy, 800 mg daily is often sufficient, especially if patients cannot tolerate higher doses. In adjunctive therapy, doses up to 1600 mg daily may be employed if seizure control is inadequate at lower doses. Tablets may be swallowed whole or crushed, and administration is not affected by meals.

Adolescents

In pediatric patients aged 4 years and older, dosing is weight-based with careful titration. For children weighing 11 to 21 kg, initial dose starts at 200 mg once daily, increasing by no more than 200 mg weekly, with maintenance doses of 400 to 600 mg daily and maximum 600 mg. For 22 to 31 kg, initial dose is 300 mg daily with increments of 300 mg weekly, maintenance 500 to 800 mg, max 800 mg daily. For 32 to 38 kg, initial 300 mg with increments of 300 mg weekly, maintenance 600 to 900 mg, max 900 mg daily. For children >38 kg, initial 400 mg daily, increments up to 400 mg weekly, maintenance 800 to 1200 mg, max 1200 mg daily. Tablets may be swallowed whole or crushed; dosing independent of meals.

Special Populations

Patients with renal impairment require dose adjustments due to decreased clearance of eslicarbazepine. Caution is advised with lower initial doses and slower titrations. Hepatic impairment has minimal effect but requires monitoring. Aptiom is not approved for use in children under 4 years. Use during pregnancy should be carefully considered due to potential risks; abrupt discontinuation is contraindicated. Eslicarbazepine is excreted in breast milk, thus breastfeeding is not recommended during therapy. Elderly patients may have altered pharmacokinetics and increased sensitivity; dose adjustments based on tolerability and renal function are advised. No dosage adjustments are needed solely based on gender.

Mechanism Of Action

Eslicarbazepine, the active metabolite of eslicarbazepine acetate (Aptiom), exerts its anticonvulsant effects primarily through stabilization of neuronal membranes by blocking voltage-gated sodium channels (VGSCs). By inhibiting the rapid influx of sodium ions during neuronal depolarization, eslicarbazepine reduces the excitability of hyperactive neurons and prevents repetitive firing that leads to seizure activity. This action preferentially affects neurons exhibiting high-frequency discharges typical of epileptic foci, contributing to its selective antiepileptic efficacy.

At the molecular level, eslicarbazepine preferentially binds to the inactivated state of VGSCs, prolonging their inactive status and thus decreasing the ability of neurons to initiate abnormal action potentials. This results in modulation of the fast inactivation phase of the sodium channel, dampening pathological neuronal hyperexcitability without significantly impairing normal neuronal function.

Additionally, eslicarbazepine has been shown to modulate calcium channel activity indirectly and possibly influence potassium channels, contributing to its overall stabilizing effect on neuronal excitability. Unlike some related anticonvulsants, eslicarbazepine has minimal interaction with cytochrome P450 enzymes, resulting in a lower potential for drug-drug interactions.

Clinically, this targeted mechanism translates into efficacy in reducing partial-onset seizures both as monotherapy and adjunctive therapy. Comparative studies suggest eslicarbazepine maintains a favorable side effect profile with once-daily dosing, improving compliance compared to older agents.

Pharmacological Actions

Stabilizes neuronal membranes by blocking voltage-gated sodium channels
Reduces neuronal hyperexcitability and repetitive firing
Prolongs inactivation state of sodium channels, decreasing abnormal action potentials
Decreases seizure susceptibility in partial-onset epilepsy
Exhibits minimal cytochrome P450 metabolism, reducing interaction potential
Once-daily dosing due to pharmacokinetic profile
Potential modulation of other ion channels (e.g., calcium, potassium) enhancing anticonvulsant effects
Improves seizure control as monotherapy and adjunctive therapy
Maintains efficacy with improved tolerability in pediatric and adult populations
Reduces nerve impulse transmission associated with seizures and neuropathic pain (off-label)

Therapeutic Clinical Uses

Treatment of partial-onset (focal) seizures in adults and children aged 4 years and older
Monotherapy for newly diagnosed or previously untreated partial-onset seizures
Adjunctive therapy for partial-onset seizures inadequately controlled by other antiepileptics
Off-label use for certain types of neuropathic pain and nerve pain (limited evidence)
Considered in patients who are intolerant to other anticonvulsants
Management of epilepsy to reduce seizure frequency and severity
Alternative to carbamazepine or oxcarbazepine with potentially improved tolerability
Improves quality of life by enabling once-daily dosing
May be used in combination regimens for refractory epilepsy cases
Applicable in pediatric epilepsy treatment from age 4 years onwards

Side Or Adverse Effects

Dizziness and drowsiness, prominent neurological side effects
Headache
Fatigue and malaise
Nausea and vomiting
Coordination difficulties, including ataxia and balance issues
Tremor and feelings of shakiness
Diplopia (double vision)
Hyponatremia (low blood sodium levels) which can be severe and life-threatening
Serious allergic reactions including rash, fever, swollen glands, possibly Stevens-Johnson syndrome or toxic epidermal necrolysis
Mood changes such as depression, anxiety, agitation, or suicidal ideation
Liver function abnormalities including hepatitis or jaundice
Blurred vision and visual disturbances
Increased seizure frequency or status epilepticus upon abrupt discontinuation
Gastrointestinal disturbances such as abdominal pain or indigestion
Potential for blood dyscrasias (rare)

Precautions

Do not abruptly discontinue Aptiom to avoid increased seizure risk
Monitor serum sodium periodically due to risk of hyponatremia
Use caution in patients with renal or hepatic impairment
Regular psychiatric evaluation recommended due to risk of mood changes and suicidal thoughts
Monitor for signs of severe hypersensitivity or severe skin reactions
Inform patients about possible dizziness or somnolence affecting driving or machinery operation
Adjust dosing carefully in pediatric patients and elderly populations
Avoid use in patients with hypersensitivity to eslicarbazepine or oxcarbazepine
Use effective non-hormonal contraception as Aptiom can reduce efficacy of oral contraceptives
Breastfeeding is not recommended during treatment due to drug passage into milk
Assess liver function prior to and during prolonged therapy
Note potential interference with some laboratory tests
Educate patients to report any signs of infection or unusual bruising
Assess for possible drug interactions, especially with other antiepileptics

Warnings

Sudden withdrawal may precipitate status epilepticus or increased seizures
Serious skin reactions and hypersensitivity reactions can be fatal; immediate discontinuation required
Risk of hyponatremia; life-threatening electrolyte imbalance may occur
Potential for suicidal thoughts or behavior; monitor patients closely, especially during early therapy
May impair cognitive and motor skills; advise patients regarding driving and operating machinery
Monitor liver function due to risk of hepatotoxicity
Use cautiously in patients with mood disorders or history of depression
Avoid use in patients with known hypersensitivity to eslicarbazepine or structurally related drugs
Pregnancy category and risk: fetal risk not fully established; weigh benefits vs risk
Eslicarbazepine can reduce contraceptive efficacy, increasing risk of unintended pregnancy
Risk of hematologic toxicity with unusual bruising or infection symptoms

Contraindications

Known hypersensitivity to eslicarbazepine acetate or any component of the formulation
Allergy or hypersensitivity to oxcarbazepine due to cross-reactivity risk
Patients with prior severe dermatologic reactions to anticonvulsants
Use in children under 4 years of age is not approved
Concurrent use with monoamine oxidase inhibitors (MAOIs) is not recommended
Severe hepatic impairment with compromised metabolism (use with caution)
Patients with significant blood dyscrasias or hematologic disorders without proper monitoring
Pregnancy without careful medical supervision due to potential fetal harm
Known severe hyponatremia at baseline contraindicates use
Patients with severe renal impairment without dose adjustment and monitoring

Drug Interactions

Eslicarbazepine can reduce the efficacy of hormonal contraceptives by inducing hepatic enzymes
Concomitant use with other antiepileptic drugs may alter serum concentrations necessitating dose adjustments
Interactions with statins such as rosuvastatin and simvastatin may increase statin levels or risk of adverse effects
Proton pump inhibitor omeprazole may affect eslicarbazepine metabolism or vice versa
Potentially additive central nervous system depressant effects when combined with benzodiazepines or opioids
Minimal interaction with cytochrome P450 enzymes reduces interaction risk, but caution advised
May decrease plasma levels of drugs metabolized by CYP2C9 and CYP3A4
Concomitant use with lithium may increase risk of neurotoxicity
Drugs that lower serum sodium levels may potentiate hyponatremia risk
Monitoring is recommended when combined with other sodium channel blockers to avoid toxicity
Potential interaction with valproate may alter drug levels
Use cautiously with other CNS-active agents to avoid excessive sedation or cognitive impairment
Avoid or monitor use with anticoagulants and immunosuppressants due to altered disposition

Preparations Of The Drug

Oral tablets: 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg strengths
Tablets are film-coated and designed for once-daily administration
Tablets can be swallowed whole or crushed for easier ingestion
Available as generic eslicarbazepine acetate formulations as well as branded Aptiom
Supplied in bottles or blister packs depending on manufacturer
No injectable or other parenteral formulations currently available
Tablets to be stored at room temperature away from moisture and heat
Prescribed for monotherapy or adjunctive therapy in epilepsy treatment protocols
Non-hormonal contraceptive methods recommended adjunct during therapy
Available in controlled distribution programs due to monitoring requirements